Degradation of cellular proteins through ubiquitination is a fundamental strategy for regulating biological pathways. De-ubiquitination, i.e. the removal of ubiquitin from proteins and peptides to which ubiquitin is attached, is catalyzed by processing proteases known as de-ubiquitinating enzymes. We are studying the biology of a family of de-ubiquitinating enzymes, the mammalian ubiquitin-speci®c proteases (USPs), some of which appear to play a role in growth control. Given the fact that the modes of regulation of USPs and of their substrate speci®city are poorly understood, we decided to attempt the identi®cation of USP interacting proteins. Using the yeast two-hybrid system (2HS), we have isolated a cDNA clone whose product speci®cally interacts with USP10 but not with other USP baits tested. The isolated clone encodes a protein known to interact with the Ras-GTPase activating protein (G3BP). This interaction was further con®rmed by performing a 2HS with G3BP, which led to the isolation of USP10 encoding cDNAs. We validated the interaction between the two proteins by performing in vitro binding assays and immunoprecipitations in human cells. G3BP does not appear to be a substrate of USP10; it rather inhibits the ability of USP10 to disassemble ubiquitin chains. The USP10/G3BP complex appears to co-immunoprecipitate with ubiquitinated species that could be substrates of USP10. Oncogene (2001) 20, 3869 ± 3879.
Introduction
Several important regulatory and structural proteins are subject to modi®cation by the attachment of ubiquitin or ubiquitin like proteins. The speci®c attachment of ubiquitin molecules to a particular substrate is highly regulated. Ubiquitination is achieved through a cascade of reactions that involve ®rst a ubiquitin activating enzyme (E1), which in the presence of ATP is linked to ubiquitin through the formation of a thioester bond. Ubiquitin is then transferred to a ubiquitin conjugating enzyme (E2). The speci®c targeting of a protein substrate is then achieved through its interaction with both a speci®c E2 and a ubiquitin ligase (E3), leading to the formation of isopeptide bonds. In yeast, an E4 function has also been described, which might have the role of extending the ubiquitin trees (Koegl et al., 1999) . The degradation steps that follow protein ubiquitination occur on the proteasome. The 26S proteasome will recognize the ubiquitinated target and will induce its degradation through an ATP dependent unfolding process. Ubiquitination also acts as a targeting signal, delivering the modi®ed protein to dierent locations in the cell and potentially modifying its activity, interactions or halflife (for review, see Hershko and Ciechanover, 1998; Laney and Hochstrasser, 1999) .
Hydrolysis of ubiquitin conjugates is needed to regenerate free ubiquitin from branched ubiquitin generated post-degradation, but also to generate free ubiquitin subunits from the synthesized linear polyubiquitin chains or from ubiquitin fusion proteins. It has also been hypothesized that protein ubiquitination can be a reversible process and that speci®c substrates can be de-ubiquitinated by USPs. The existence of active de-ubiquitinating activities is also supported by the ®nding that inhibition of the proteolytic activity of the proteasome, while inducing the accumulation of protein substrates does not result in an increase in their overall ubiquitination.
De-ubiquitination is catalyzed by specialized thiol proteases known as de-ubiquitinating enzymes (for a recent review see Ciechanover et al., 2000) . These enzymes hydrolyze the amide bond between the Cterminal glycine residue of ubiquitin and primary amino groups of the substrate protein. More than 60 de-ubiquitinating enzymes have been identi®ed thus far in genome databases, and they are commonly divided in two distinct families: Ubiquitin C-terminal Hydrolases (UCH) and Ubiquitin-Speci®c Proteases (USPs) (D'Andrea and Pellman, 1998; Wilkinson, 1997; Wilkinson and Hochstrasser, 1998) . We are interested in studying the biology and biochemistry of mammalian USPs, also known as UBPs (ubiquitin isopeptidases), they presently form the largest enzyme family in the ubiquitin system and are characterized by a core region containing conserved regions, the Cys and His boxes (Baker et al., 1992) , surrounded by divergent sequences, most commonly at the N-terminal end. The N-terminal end is likely responsible for enzyme speci®city and/or for controlling subcellular localization (Lin et al., 2000) . In addition, there are indications that distinct USPs could have specialized functions.
Genetic investigations in yeast and in Drosophila have identi®ed certain USPs as critical regulators of biological processes such as ubiquitin homeostasis (Papa and Hochstrasser, 1993; Swaminathan et al., 1999) , gene silencing (Moazed and Johnson, 1996) and development (Huang et al., 1995) . Genetic evidence would in fact indicate that mutation in selected USP genes can aect a given biological pathway (Cadavid et al., 2000) . The speci®c phenotypes resulting from the disruption of genes encoding such USPs demonstrated that USPs could have a high degree of substrate speci®city (Moazed and Johnson, 1996; Huang and Fischer-Vize, 1996) .
USP deregulation has been detected in cancer. It has been shown that overexpression of a mouse cDNA encoding Unp (USP4) leads to oncogenic transformation of NIH3T3 cells (Gupta et al., 1993) . The human Unp mRNA levels were found to be elevated in small cell lung carcinomas and adenocarcinomas of the lung, suggesting its involvement in tumorigenesis (Gray et al., 1995) , although a study describes results that are inconsistent with the previous ®ndings (Frederick et al., 1998) . Recently, a cDNA encoding Dub-1, a mouse USP, was found in the course of a screen for cytokine regulated genes. Dub-1 overexpression results in the induction of growth arrest, leading to the suggestion that it might have growth suppressive ability in vivo (Zhu et al., 1996) . The same group isolated a highly related protein Dub-2, that is speci®cally induced by IL-2 (Zhu et al., 1997) . We have previously characterized a novel human USP, USP8 (UBPY) which has deubiquitinating activity in vitro and in vivo, and we have shown that microinjection of anti-USP8 prevents ®broblasts from entering S phase in response to serum stimulation (Naviglio et al., 1998) . Two additional USPs have recently also been identi®ed and characterized in vitro Sloper-Mould et al., 1999) .
We used a two-hybrid screen to isolate potential USP interactors. Here we demonstrate that USP10 is a de-ubiquitinating enzyme and that it interacts in vitro and in vivo with G3BP, a protein involved in the Ras signal transduction pathway (Parker et al., 1996) . G3BP does not appear to be a substrate of USP10; it rather inhibits USP10 activity. Our data demonstrate that the two proteins are part of a complex that likely regulates USP10 function in vivo.
Results

USP10 cloning and characterization
A cDNA encoding a potential USP was found in GenBank (accession number D80012). Using the ®rst 1200 bp of this cDNA (a kind gift from N Nomura) as a probe, we screened a human cDNA library to identify any potentially longer clone. All the positive clones obtained from the screen were found to have the same DNA sequence and a 5' in-frame stop codon. The third ATG in the clone is likely the starting codon having the strongest Kozac consensus; it is also conserved in a highly similar mouse cDNA (GenBank accession number D84096). The identi®ed ORF encodes a protein of 848 amino acid residues with a predicted MW of 92 900 Da. It contains regions matching the consensus cysteine and histidine boxes typical of the USP family of de-ubiquitinating enzymes (Figure 1a ). According to the nomenclature proposed by the Human Genome Organization (HUGO) Nomenclature Committee (http://www.gene.ucl.ac.uk/ nomenclature), we are calling the encoded protein USP10. Figure 1b shows the characterization of an anti USP10 polyclonal antiserum. The antiserum recognized a band of about 100 kDa in a cell lysate. In vitro translated protein was also recognized by the antiserum and it comigrated with the band detected in the cell lysate. USP10 was ubiquitously expressed both at the RNA and at the protein level, with increased abundance in transformed cells compared to normal ones (C Soncini, Maria Capra and GF Draetta, 2001, unpublished) .
We then expressed USP10 as a glutathione Stransferase (GST) fusion protein in E. coli and after purifying it on a glutathione-Sepharose column, assayed its de-ubiquitinating activity using a previously characterized arti®cial USP substrate, an HA-tagged ubiquitin hexamer (HA-Ub6) (Naviglio et al., 1998) . It has been demonstrated that such epitope-tagged ubiquitin can be conjugated correctly in vivo and in vitro to cellular proteins which then become targets of proteolytic cleavage by the proteasome (Ellison and Hochstrasser, 1991; Treier et al., 1994; Hateboer et al., 1996; Diehl et al., 1997) . We could not detect any activity under these conditions. On the contrary, upon expressing the putative USP10 catalytic domain as GST-fusion protein in bacteria, we could readily detect activity.
We wanted to exclude the possibility that lack of activity in the full-length USP10 protein might be due to misfolding or lack of post-translational modi®ca-tions. To this end, we generated a His6-tagged fulllength wild-type construct and one carrying a Cys-toAla mutation in the putative active site cysteine. These were expressed in baculovirus-infected insect cells, puri®ed and tested for activity in the assay. Indeed, upon incubating Ha-Ub6 with increasing amount of puri®ed baculovirus, expressed full-length wild-type USP10 we could readily detect activity (Figure 2 ). When assayed under the same conditions, the protein mutated in the putative active site cysteine was inactive. Degradation was dose dependent and completely abolished by the addition of 5 mM N-ethyl maleimide (NEM), a known inhibitor of de-ubiquitinating enzymes (Stein et al., 1995; Wilkinson et al., USP10 a novel human ubiquitin specific protease C Soncini et al 1995) (Figure 2 ). We obtained similar results using USP10 immunoprecipitated from human cell extracts (not shown). USP10 activity could also be detected using a ubiquitin isopeptide dimer as a substrate (Figure 3a) . We found that overexpression of wild-type USP10 in cells transfected with HA-Ub caused a decrease in protein ubiquitination (Figure 3b ). In the same experiment, a construct encoding a Cys to Ala mutant was completely inactive (Figure 3b ). This demonstrated that USP10 overexpression can eectively drive protein de-ubiquitination.
G3BP is a USP10 interacting protein
To identify potential USP10 substrates and/or modulators of its function, we performed a yeast twohybrid screen. The bait was constructed to express a fusion protein between the LexA DNA binding domain (amino acids 1 ± 211) and the full-length USP10 cDNA. We screened both a mouse embryo and a human lymphocyte cDNA library. Two highly similar cDNA clones were identi®ed in both libraries, which were also the most represented among the positives obtained from either screen. The cDNAs were found to encode GAP SH3-binding protein (G3BP), a protein previously characterized as binding the SH3 domain of Ras ± GTPase Activating protein (Ras ± GAP) (Parker et al., 1996) . By direct two-hybrid, we found that the interaction occurred only with USP10 (either the wild-type protein or a Cys-to-Ala mutant) but not with two other USPs used as baits. Along with USP10, we tested USP8 (UBPY) (Naviglio et al., 1998) and USP4 (UNPH) (Frederick et al., 1998; Gray et al., 1995) . Neither of the two interacted with G3BP in this system. The speci®city of this interaction was also demonstrated by the fact that a region comprising the amino terminus of USP10, which does not contain the catalytic site and is poorly conserved between the dierent UBPs, was sucient for USP10 interaction with G3BP ( Figure 4a) .
We also performed a two-hybrid screen with the G3BP full-length cDNA as a bait, and identi®ed among 20 clones a clone encoding amino acids 52 ± 280 of USP10 ( Figure 4b ). This result con®rmed the speci®city of the detected interaction between G3BP and USP10 even further and prompted us to continue to investigate its role. We then set-up a binding assay using in vitro translated G3BP and the GST ± UBPO Samples were collected at dierent time point and loaded on a SDS ± PAGE. Western blot was performed with an anti ubiquitin antibody. IP with preimmune serum was used as negative control. (b) U2OS cells were co-transfected with 10 mg of HAUb plasmid and 10 mg of pCMV empty vector (EV), pCMV ± USP10 wild-type Cys to Ala mutant (M). Lysates were subjected to SDS ± PAGE (8%) and to anti-USP10 or anti-HA immunoblotting USP10 a novel human ubiquitin specific protease C Soncini et al protein. Figure 5a shows that G3BP could interact with USP10 in vitro; the GST moiety alone did not appear to interact signi®cantly with G3BP. Similar results were obtained upon using GST ± G3BP and in vitro translated USP10 (not shown).
To test whether this interaction occurs in living cells we performed a co-immunoprecipitation experiment. A lysate obtained from the human osteosarcoma cell line U2OS was incubated with either an anti-USP10 monoclonal antibody or with an anti-G3BP polyclonal antiserum, and immunoprecipitations were performed followed by immunoblotting with either antibody. As shown in Figure 5b , we could demonstrate that the two proteins interact in intact cells. The speci®city of the interaction between USP10 and G3BP was also demonstrated by the absence of a signal using an anti-USP8 monoclonal antibody or a preimmune serum. We obtained the same result using lysates from dierent cell lines. The interaction between the two proteins appeared to be stable and we could detect it both in growing and quiescent (serum starved) human ®broblasts. In comparison, G3BP only appears to interact with Ras ± GAP in growing but not in quiescent cells (Gallouzi et al., 1998) .
USP10 and G3BP are part of a high molecular weight complex
To explore the hypothesis that USP10 and G3BP could be part of larger complex that might even contain USP10 substrates, we analysed protein complexes after treatment with the chemical crosslinker EDC (see Materials and methods). Similar experiments were performed by Gallouzi et al. (1998) to show a direct interaction between RasGAP and G3BP. As shown in Figure 6 , immunoblotting with either anti-G3BP or anti-USP10 antibodies of crosslinked lysates revealed high Mr. immunoreactive bands. Using an anti-G3BP antibody on the crosslinked lysate we noticed a band of approximately 180 kDa that could correspond to the RasGAP ± G3BP complex described by Gallouzi et al. (1998) ; in the same lane the complete disappearance of the G3BP band was also evident (Figure 6a ). We were also able to immunoprecipitate the higher band with both anti-G3BP and anti-USP10 antibodies ( Figure  6a ). In our experimental conditions this band was not recognized by an anti RasGAP antibody. This high molecular weight complex must obviously contain Figure 4 Schematic representation of the LexA fusion proteins used and two-hybrid assay. (a) The S. cerevisiae strain L40 was transformed with the indicated pLexA and pV16 plasmids and b-Galactosidase activity (average of three independent transformations) was measured by a ®lter assay for strains expressing the indicated fusion proteins. (b) Schematic representation of G3BP and USP10. Arrows below the schema indicate the longer insert ®shed out by two-hybrid with USP10 (---) and G3BP (-.-). RNP, RNA binding motif; RG, arginine glycine rich region; C, cysteine box; H, histidine box USP10 and G3BP, and possibly other, yet unidenti®ed, components.
Association of G3BP and USP10 with ubiquitinated species
We tested whether G3BP is a substrate of G3BP. After treating human U2OS or HeLa cells with the proteasome inhibitor MG132, we prepared cell lysates and performed immunoblotting with anti-G3BP antibody. The protein level remained constant (Figure 7a ) whereas the level of b-catenin (which is known to be turned over rapidly through ubiquitination and proteasome dependent degradation (see Maniatis, 1999 for review)) increased substantially as a result of the treatment. This allows us to conclude that under the tested conditions G3BP is quite stable and unlikely to be degraded through the ubiquitin ± proteasome pathway. Upon immunoprecipitation of lysates from cells transfected with a plasmid expressing HA-tagged ubiquitin and treated with MG132, with the anti-G3BP antibody we could detect slow migrating bands typical of ubiquitinated proteins (Figure 7b ). These bands were detected by immunoblotting with an anti-HA antibody. Similar results were obtained by treating non-transfected cells with MG132 and immunoblotting with an anti-ubiquitin antibody (not shown). Interestingly, transfection of a USP10 cDNA, but not of a USP8 or 4 construct, was able to inhibit the accumulation of these ubiquitin-containing bands (not shown), suggesting that USP10 could be the speci®c enzyme regulating this reaction.
To verify whether the ubiquitinated bands associated with G3BP were due to G3BP ubiquitination, we performed an immunoprecipitation from a cell lysate subjected to a denaturing treatment with SDS (see Materials and methods). As shown in Figure 8 , ubiquitin-containing bands disappeared upon treatment, indicating the possibility that ubiquitinated proteins other than G3BP can interact with G3BP and USP10.
To test whether G3BP could alter USP10 activity we performed an in vitro de-ubiquitination assay in the presence of G3BP. HA-Ub6 substrate was incubated with recombinant USP10 puri®ed from insect cell lysates (®nal concentration 10 77 M) in the presence of GST ± G3BP. The de-ubiquitination of HA-Ub6 was strongly inhibited by GST ± G3BP (Figure 9a ). Very slight inhibition was detected upon adding GST alone (Figure 9c ). Moreover, GST ± G3BP did not appear to inhibit USP8 (Figure 9b ), once again demonstrating the speci®city of the interaction between G3BP and USP10. We conclude, therefore, that G3BP negatively regulates the activity of USP10.
Discussion
In this report we describe the characterization of USP10, a new ubiquitin-speci®c protease. The recombinant USP10 protein produced using a baculovirus system and puri®ed, can cleave ubiquitin chains eciently. Similar results can be obtained when USP10 is immunoprecipitated from cell lysates. We could also detect de-ubiquitinating activity using a fragment comprising the C-terminal domain of USP10, which contains the conserved Cys and His boxes of USPs. In contrast, we were unable to detect de-ubiquitinating activity associated with the GST fulllength protein expressed in bacteria, probably due to misfolding or to the need of post-translational modi®cations. A post-translational modi®cation of USP10 might indeed explain why the protein runs on SDS ± PAGE at approximately 100 kDa while its calculated MW is 92 900.
The biological role of USP10 is unknown at present. Using USP10 as a bait in the two-hybrid screen, we isolated G3BP, a RasGAP associated protein, recently Increasing amount of GST and GST ± USP10 fusion proteins were incubated with the in vitro translation product of G3BP as described in Materials and methods. The protein complexes were separated on a 10% SDS polyacrylamide gel. Two ml of the in vitro translation reaction is shown as control. (b) Co-immunoprecipitation experiment. U2OS cell lysate was incubated with anti USP10 monoclonal antibody or anti G3BP polyclonal antibody and Western blotted with both antibodies. USP8 monoclonal antibody and a polyclonal preimmune serum were used as control USP10 a novel human ubiquitin specific protease C Soncini et al
shown to be overexpressed in tumors (Guitard et al., 2001) . We demonstrated that G3BP can bind USP10 in vitro and that the two proteins are associated in vivo.
The amino terminal region of USP10, which is not part of the domains conserved among the various USP family members, is sucient for its interaction with G3BP. Indeed, we found that G3BP speci®cally interacts with USP10 and not with the other USPs tested. G3BP was ®rst described as a protein that binds eciently the SH3 domain of RasGAP. This interaction occurs only in proliferating cells, suggesting a recruitment of GAP ± G3BP complex when Ras is in its Figure 6 Chemical cross-linking analysis. U2OS total cells extract was treated with EDC and cross-linked lysate was analysed by immunoblotting with both anti G3BP (a) and anti USP10 (b) antibody. Also shown is immunoprecipitation with anti USP10 monoclonal antibody (a). The high molecular bands obtained by EDC treatment are labeled (*) Figure 7 G3BP co-immunopuri®cation with ubiquitinated species. (a) U2OS and HeLa cells were treated for 12 h with 20 mM MG132 proteasome inhibitor. G3BP protein level was assayed by Western blot analysis with anti G3BP immunopuri®ed polyclonal antibody. b-catenin was used as treatment control. (b) U2OS cells were transfected with Ha-Ub6 and treated with MG132. Cell lysate was immunoprecipitated with either anti G3BP polyclonal antibody or a preimmune serum and then blotted with an anti HA monoclonal antibody active conformation (Parker et al., 1996) . A fraction of G3BP co-localizes with RasGAP at the plasma membrane, while much of the protein is cytosolic (Gallouzi et al., 1998) . G3BP has two RNA binding consensus motifs RNP1 and RNP2 and an RGG box. G3BP also co-puri®es with a ribonuclease activity, which is only detected when G3BP is in its hyperphosphorylated state (Gallouzi et al., 1998) . A new DNA helicase complex was isolated which contains G3BP (Costa et al., 1999) . More recently it was shown that G3BP is overexpressed in human tumors and that its overexpression promotes S phase entry in serum starved ®broblasts (Guitard et al., 2001) . It was also demonstrated that this function is dependent on having an intact RNP domain.
G3BP does not appear to be a short-lived protein under the conditions examined and it does not appear to be ubiquitinated in either in vitro or in intact cells. It is unlikely, therefore, that G3BP itself is a substrate of USP10. In support of this Gallouzi et al. (1998) showed that the levels of G3BP protein are constant throughout the cell cycle. We observed that ubiquitinated bands can be detected in association with G3BP in lysates prepared from cells treated with the proteasome inhibitor MG132 (Figure 7b ). These bands did not cross react with either USP10 or G3BP antibodies and are likely due to the ubiquitination of other proteins present in this complex. Since G3BP can associate with RasGAP, we tested whether RasGAP was a target for ubiquitin-dependent proteolysis. We did not detect any increase in RasGAP protein level upon addition of proteasome inhibitors. In addition we were unable to co-precipitate the G3BP complex with RasGAP, although we cannot exclude that this could be due to the fact that our antibodies recognize epitopes that are involved in such interactions. Recently a mouse cDNA clone encoding a deubiquitinating enzyme (mUBPY) was isolated as a SH3 binding protein (Kato et al., 2000) and a novel SH3 domain binding site was de®ned. We were unable to ®nd any SH3 binding site or domain in the USP10 sequence.
Chemical cross-linking of cell lysates followed by immunoblotting with anti USP10 and G3BP revealed a high molecular band that was immunoprecipitated by either antibody. This ®nding, together with the fact that by FPLC fractionation G3BP and USP10 copurify in some high molecular weight fractions (not shown), suggest that USP10 and G3BP are part of a large macromolecular complex that contains other proteins including perhaps a USP10 substrate. We tried a classical biochemical puri®cation of this complex by anity chromatography using GST ± USP10 against a cell lysate but we were able only to identify G3BP among the puri®ed bands. By twohybrid screening with G3BP as a bait, we have identi®ed USP10 (see above) but also a number of clones that potentially represent candidate USP10 substrates.
G3BP appears to aect the activity of USP10. Upon adding G3BP to the de-ubiquitinating assay we saw an inhibition of USP10 activity. This eect was speci®c since G3BP did not inhibit the de-ubiquitinating activity of other USPs (Figure 9) . The mechanism of inhibition should not involve competition at the active site since G3BP doesn't bind the catalytic domain of USP10.
The involvement of USPs in Ras signaling has been demonstrated. It has been reported that Ras1 interacts genetically with the Fat facets (Faf) gene during Drosophila eye development. Analysis of this interaction reveals that Faf has an additional function later in eye development involving Ras1 (Li et al., 1997) . Moreover the Faf related protein Fam was shown to interact with b-catenin and AF-6, an eector of Ras, and to prevent their ubiquitination (Taya et al., 1998 (Taya et al., , 1999 . Our ®nding of a physical interaction between G3BP, a RasGAP interacting protein and USP10 could provide further links between the ubiquitination pathway and Ras-mediated signaling. Future experiments will test whether the association between USP10 and G3BP (and perhaps Ras ± GAP) and the inhibitory activity of G3BP on USP10 changes during the dierent phases of the cell cycle or upon dierent growth stimuli.
Materials and methods
Isolation of human USP10 and G3BP full length USP10 partial cDNA (GenBank accession number D80012) was ®rst identi®ed in human myeloblast cell line KG1 by Nomura et al. (1994) . A human cDNA library prepared from ML1 cells and cloned in Lambda Zap Express (kind gift of Kristian Helin) was screened with the ®rst 1200 bp of USP10 partial cDNA. The probe was labeled with 32 PdCTP by random primer method (Amersham), and hybridization was performed in: 56 Denhard's solution, 0.5% SDS, 56 SCC and 100 mg/ml salmon sperm DNA for 16 h at 658C. A total of 1610 6 recombinant phages were screened and 80 positives were found. Sixteen positive plaques were identi®ed from the secondary screening. These plaques were screened then by PCR using pfu DNA polymerase (Stratagene) and the primers utilized are: T3 universal primer as the upstream primer, and an internal USP10 primer with the following sequence:
5'-CGAGGAGTCACAAAAGAATTG-3' as downstream primer. The resulting PCR products were cloned directly into pCR 2.1 vector (Invitrogen) and screened for inserts by restriction digestion. Clones containing the largest inserts were selected for sequencing. These clones provided the 5' region of USP10 cDNA were cloned into pBSKKIA190 by insertion at the HincII and EcoRI sites to generate a putative full-length.
Human G3BP cDNA was obtained by PCR screening of a cDNA library made from human lung embryo ®broblast (kind gift of Pier Paolo Di Fiore). The reaction was performed using pfu DNA polymerase (Stratagene) and the following primers, designed on the human G3BP cDNA sequence (GenBank accession number U32519): 5'-GAC-CAAAGCAATGGTGATGG-3' as upstream primer and 5'-CATGAAGATTACTGCCGTGG-3' as downstream primer. The resulting PCR products were cloned directly into pCR 2.1 vector (Invitrogen) and screened for inserts by restriction digestion. The accuracy of the cDNA was con®rmed by sequencing.
Plasmids
The Cys(488)Ala mutation was introduced into USP10 by a two step PCR-based approach. The 5'-GGAACTGGGCC-TACATTAATGC-3' and 5'-GCATTAATGTAGGCC-CAGTTCC-3' primers were used to mutate the Cys 488 codon together with the following¯anking primers: 5'-TTGTTCCGGTTTCAGAGGATCC-3', upstream the Cys codon at the BamHI site and 5'-CAGACAGGCTT-GACTTGTTAAC-3', downstream the Cys codon at the HpaI site. The ®nal PCR product was used to replace the BamHI ± HpaI wild-type fragment in the pSKUSP10 construct. The mutant was veri®ed by DNA sequencing. pGEXUSP10 was constructed by cloning the EcoRI ± NotI USP10 fragment into pGEX4 ± T1 expression vector (Pharmacia Biotech), while pGEXG3BP was obtained cloning G3BP EcoRI fragment into the same expression vector. Eukaryotic expression vector pBMN ± GFP was used to overexpress wild-type and mutant USP10. The constructs were obtained cloning the Xho ± NotI pSKUSP10 wild-type or mutant fragment in the same sites of the vector.
Yeast two-hybrid screens
A bait was made as a fusion between LexA DNA binding domain (amino acids 1 ± 211) and USP10 (amino acids 14 ± 862). The second hybrid is a fusion between a nuclear localized VP16 acidic activation domain and random cDNA fragments derived from 9.5 and 10.5 day-old mouse embryos (kind gift of Isabel Chiu). These two hybrids are co-expressed in the S. cerevisiae strain L40 that contains two integrated reporter constructs, the yeast HIS3 gene and the bacterial lacZ gene, which contain binding sites for the LexA protein.
Approximately 10 8 yeast transforms were screened, 30 clones were found positive on Xgal/-Hist plates in the presence of 5 mM 3-aminotriazole. The recovered plasmids were subjected to restriction and sequence analysis and from this screen 10 clones were identi®ed that correspond to the same cDNA. Using the same system we screened a human lymphocyte cDNA library (Clontech) and we isolated 12 positives, one of which turned out to be the human homologous of one of the mouse clones.
In vitro binding assay GST and GSTUSP10 were produced using standard methods. Brie¯y, protein expression was induced by addition of 0.1 mM IPTG to a bacteria culture at OD 600 0.6. The bacteria were lysed after 4 h of growth at 378C, in 1% Triton in PBS plus 1 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml pepstatin, 1 mg/ml leupeptin.
After sonication and centrifugation, the supernatant was incubated with glutathione Sepharose beads (Pharmacia) rotating for 1 h at 48C. After three washes in ice-cold PBS, bound proteins were eluted with 10 mM glutathione in 50 mM Tris HCl pH 8.0. Full-length human G3BP was in vitro translated using TNT reticulocyte lysate (Promega) following the instructions of the manufacturer. Binding reactions were performed in 600 ml of 20 mM HEPES pH 7.4, 150 mM NaCl, 0.05% NP40, 10% glyerol; for 1 h at 48C, using from 5 to 20 mg of GST fusion proteins and 15 ml of the in vitro translated product. Glutathione Sepharose was added (30 ml from a 50% slurry) and the reactions continued for 30 min with rotation. The beads were pelleted, washed three times in the binding buer, resuspended in 26 Laemmli sample buer and heated at 958C for 10 min. After separation on a SDS ± PAGE the gel was dried and exposed.
Immunoprecipitation and immunoblotting
Protein extracts was prepared from human U2OS, HeLa or IMR90 cell line by scraping the cells directly in lysis buer: 50 mM Tris HCl pH 7.4, 150 mM NaCl, 1% Triton, 5 mM EGTA, 1.5 mM MgCl 2 , 10% glycerol, 50 mM NaF, 1 mM Na 3 VO 4 , 0.5 mM EDTA, 1 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml pepstatin, 1 mg/ml leupeptin. Lysates were incubated on ice for 20 min and then centrifuged at 14 000 r.p.m. for 15 min at 48C. Supernatants were assayed for total protein using the Bradford method (BioRad) according to the instructions provided. For immunoprecipitation: typically 1 mg of cells lysate was diluted to 500 ml with NET buer (50 mM Tris HCl pH 7.4, 150 mM NaCl, 0.1% Triton, 1 mM EDTA) and incubated on ice for 60 min, in the presence of 2 ml of rabbit polyclonal antiserum or 200 ml of monoclonal supernatant. Fifty ml of 50% slurry of Protein A-Sepharose (Pharmacia) were added and the reactions incubated for 30 min at 48C on a gentle-rotating mixer. Pellets were washed three times with NET buer resuspended in 20 ml of 26 Laemmli sample buer and heated at 958C for 10 min prior to loading on a 8% SDS ± PAGE. Immunoblotting was performed according to standard methods. The ECLenhanced chemiluminescence kit (Amersham) was used for detection.
Antiserum
Polyclonal anti-USP10 and anti-G3BP antiserums were generated by PRIMM (Milan, Italy). Rabbits were injected with puri®ed GSTUSP10 or GSTG3BP fusion proteins. Monoclonal antibody were raised using the same antigens. Mouse anti ubiquitin antibody was purchased from ZYMED Laboratories Inc. and monoclonal anti HA antibody from BabCO.
Chemical cross-linking
Proliferating human U2OS or IMR90 cells were collected, lysed and treated with 10 mM 1-ethyl-3(dimethylamino)-propyl carbodimide (EDC) as described (Gallouzi et al., 1998) with minor modi®cation.
De-ubiquitinating assay
The assay mixtures (50 ml) contained reaction buer (50 mM Tris HCl pH 7.4, 0.1 mM EDTA, 1 mM DTT), and recombinant puri®ed USP10 or USP 8 (kind gift of Dr Jorge Dominguez) from insect cells infected with baculovirus expressing His tag USP10 or USP 8 (from 10 up to 100 nM), was incubated from 0 to 2 h at 378C, with 0.18 mg of recombinant Ha-ubiquitin six-mer (Ub6). Ten ml were taken each time point and the reaction was stopped adding 10 ml of 26 Laemmli sample buer and heated at 958C for 5 min. The products were analysed by 10% SDS ± PAGE, and blotted against anti-HA puri®ed MBA. Five mM N-ethylmaleimide (NEM) was used as UBPs chemical inhibitor. The cDNA encoding HA-tagged ubiquitin was excise from the parental plasmid pMT123 (Treier et al., 1994) and insert into pET23 bacterial expression vector to transform BL21 bacteria. Puri®cation of the recombinant HAUb6 from bacterial supernatant was performed onto S200 16/60 column, the cleanest fractions were pooled, concentrated and used as substrate for USP10 de-ubiquitinating activity. To test the eect of G3BP on USP10 activity 5 molar excess of GST or GSTG3BP was added to the reactions. The assay was also performed with immunoprecipitated USP10 from human cells.
Puri®cation of recombinant USP10 from insect cells infected with baculovirus expressing His tag USP10. Bac-toBac 1 Baculovirus Expression Systems (Life Technologies) was used to obtain the recombinant proteins. Wild-type and mutant USP10 were cloned into pFastBac HT expression vector (Life Technologies) contain 6x-histidine tag. Monolayer cultures of Sf9 were infected with pFastBac HT-USP10 wt or mutant. The proteins were puri®ed according to the instructions provided with minor modi®cation using ProBound TM Resin (Invitrogen) as column matrix.
